Therefore, a next generation CDK4/6 inhibitor should inhibit CDK4/6-dependent tumor growth while minimizing neutropenia, thereby reducing the need for treatment holidays and decreasing the risk of inducing drug resistance. This evidence concerns the gene CDK4 and Decreased total neutrophil count.